TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma Group Limited is navigating the approval process for its acquisition by Cosette Pharmaceuticals, which is contingent on the Foreign Investment Review Board’s (FIRB) decision. The FIRB has extended its decision deadline to 20 November 2025, and Cosette’s current debt arrangements are only available if the scheme becomes effective by 24 November 2025. The scheme’s progression is not dependent on Cosette’s current debt facilities, and Mayne Pharma is committed to enforcing its rights under the Scheme Implementation Deed. The company is closely monitoring the situation as the Second Court Hearing is scheduled for 21 November 2025, which will determine the scheme’s effectiveness by the new deadline.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel pharmaceuticals, offering patients better, safe, and more accessible medicines. It is a leader in dermatology and women’s health in the United States and provides contract development and manufacturing services globally. With a 40-year track record, Mayne Pharma has successfully developed and commercialized new oral drug delivery systems.
YTD Price Performance: -2.41%
Average Trading Volume: 450,210
Technical Sentiment Signal: Sell
Current Market Cap: A$394M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.